Abstracts presented during the
Category: 6. Business
-
Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis
CHEST annual meeting , held in Chicago, Illinois, October 19-22, 2025, showed the efficacy of brensocatib (Brinsupr; Insmed Incorporated Investor Relations) in reducing the activity of neutrophil serine proteases… -
Infinatamab Deruxtecan Shows Encouraging CNS Activity in Extensive-Stage Small Cell Lung Cancer
Infinatamab deruxtecan (I-DXd) demonstrated intracranial efficacy with acceptable safety in patients with extensive-stage small cell lung cancer (ES-SCLC) and baseline brain metastases, according to data from the primary analysis of the phase 2…
Continue Reading
-
ASCENT-03 Trial Supports Standard Use of Sacituzumab Govitecan in mTNBC
Sacituzumab govitecan (Trodelvy) reduced the risk for disease progression or death by 38% vs chemotherapy in patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible…
Continue Reading
-
Eilat home with sea view fetches NIS 6.5m
The latest deal is the most expensive ever in the neighborhood and according to the Israel Tax Authority website the biggest deal in Eilat over the past decade.
Continue Reading
-
The price of a view: In apartments, size isn't all that matters
Price gaps of over 10% between similar apartments suggest it’s time to rethink price-per-square-meter
Continue Reading
-
PepsiCo (NASDAQ:PEP) investors are sitting on a loss of 8.8% if they invested a year ago
Investors can approximate the average market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by PepsiCo, Inc. (NASDAQ:PEP)…
Continue Reading
-
ALEX Trial Final Results at ESMO 2025: Alectinib Demonstrates Durable Overall Survival and Long-Term Disease Control in Advanced ALK-Positive NSCLC
The ALEX trial (NCT02075840) represents one of the most pivotal studies in the evolution of treatment for anaplastic lymphoma kinase–positive (ALK+) non–small cell lung cancer (NSCLC). The trial’s earlier findings led to…
Continue Reading
-
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
Q: Could you summarize the magnitude of benefit seen with Dato-DXd compared to chemotherapy in this first-line mTNBC population and comment on how clinically meaningful this is for practice?
Rebecca Dent, MD: As we know, patients with metastatic…Continue Reading
-
PAM Inhibition Adds Value in HR+/HER2- PIK3CA Wild Type Advanced Breast Cancer
The addition of the PI3K/AKT/mTOR (PAM) inhibitor gedatolisib to fulvestrant (Faslodex), with or without palbociclib (Ibrance) led to clinically meaningful and statistically significant improvements in progression-free survival (PFS) among…
Continue Reading
-
DESTINY-Breast11: Neoadjuvant T-DXd/THP Improves pCR in High-Risk HER2+ BC | Targeted Oncology
Neoadjuvant fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) followed by paclitaxel, trastuzumab (Herceptin), and pertuzumab (Perjeta; THP) yielded benefit in pathologic complete response (pCR) rates compared with dose-dense doxorubicin and…
Continue Reading